Prestige Consumer Healthcare Inc. has announced the expansion of Christine Sacco's role to include Chief Operating Officer (COO) responsibilities alongside her current position as Chief Financial Officer (CFO). This move is effective immediately and is aimed at enhancing the execution of strategic initiatives and driving operational excellence across the organization. Sacco, who has been with the company for over 8 years, will now oversee the company's supply chain in addition to her existing financial responsibilities.
Sacco, a seasoned executive with more than 27 years of leadership experience in the consumer products and specialty pharma space, has been the Company’s CFO since 2016. Under her financial leadership, the company has achieved strong sales, earnings, and cash flow growth over the past 8 years. Her expanded role is expected to further drive operational excellence and long-term organic and M&A growth for the company.
Prestige Consumer Healthcare Inc. is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The company's diverse portfolio of brands include Monistat®, Summer’s Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux’s Butt Paste®, Nix®, Debrox®, Gaviscon®, and Hydralyte®.
The company's announcement did not include specific financial metrics or performance indicators for the current or previous periods. The market has reacted to these announcements by moving the company's shares -0.7% to a price of $76.35. If you want to know more, read the company's complete 8-K report here.
